Androgenetic Alopecia
Conditions
Keywords
alopecia, androgenetic alopecia, hair loss, minoxidil, 5% minoxidil foam, male pattern hair loss
Brief summary
Topical minoxidil is the most common drug used for the treatment of AGA in men. While topical minoxidil exhibits a good safety profile, the efficacy in the overall population remains relatively low i.e., 30-40% re-grow hair. To observe significant improvement in hair growth, minoxidil is typically used twice daily for a period of at least 16 weeks. Due to the significant time commitment and low response rate, a diagnostic test to identify non-responders prior to initiating therapy would be advantageous. Minoxidil is converted in the scalp to its active form, minoxidil sulfate, by the sulfotransferase enzyme SULT1A1. The enzyme expression is variable among individuals. We have demonstrated in two prior feasibility studies that the SULT1A1 enzyme activity in plucked hair follicles correlates with minoxidil response in the treatment of AGA and thus can server as a predictive biomarker. Consequently, we developed a minoxidil response in-vitro diagnostic kit intended to identify non-responders prior to initiating therapy with 5% topical minoxidil foam. The primary purpose of this study is to evaluate the clinical validity of the minoxidil response in-vitro diagnostic kit.
Interventions
5% minoxidil topical foam
Sponsors
Applied Biology, Inc.
Study design
Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
MALE
Age
18 Years to 49 Years
Healthy volunteers
No
Inclusion criteria
* Males in overall good health * Age: 18 to 49 * Diagnosed with male androgenetic alopecia with vertex pattern IIIv, IV, or V on the Norwood Hamilton Scale * Willing to have a mini dot tattoo placed in the target area of the scalp * Willing to maintain the same hair style, color, shampoo and hair products use, and approximate hair length throughout the study * Able to give informed consent * Able to comply with the study requirements for 16 consecutive weeks
Exclusion criteria
* Previous adverse event from topical minoxidil treatment * Does not use and have not used in the past 6 months anti-androgen therapy such as finasteride * Does not use and have not used in the past 6 months minoxidil (topical or oral) * Does not take medication known to cause hair thinning such as Coumadin and anti-depressants/anti-psychotics * Folliculitis * Scalp psoriasis * Seborrheic dermatitis * Inflammatory scalp conditions such as lichen planopilaris
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Sensitivity and specificity of the minoxidil response in-vitro diagnostic kit to predict at baseline the mean change in non-vellus hair count in the target region | baseline to week 16 |
| Sensitivity and specificity of the minoxidil response in-vitro diagnostic kit to predict at baseline the subjects ratings | baseline to week 16 |
Secondary
| Measure | Time frame |
|---|---|
| Sensitivity and specificity of the minoxidil response in-vitro diagnostic kit to predict at baseline the treatment efficacy evaluated by expert panel review of global photographs assessing hair regrowth | baseline to week 16 |
| Sensitivity and specificity of the minoxidil response in-vitro diagnostic kit to predict at baseline the mean change in non-vellus hair diameter in the target region | baseline to week 16 |
| Mean change in minoxidil sulfotransferase activity in plucked hairs as measured by the minoxidil response in-vitro diagnostic kit | baseline to week 16 |
Countries
Australia, India, Italy, United States
Outcome results
None listed